ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript

Question-and-Answer SessionDennis HomChief Financial Officer Sure. So the company has evolved over time, as you alluded to. But since 2022, we've been exclusively focused on developing our Axiomer technology, which is our version of RNA editing. So the strategy we're taking is fairly straightforward. We're developing our own, wholly-owned pipeline of programs based on Axiomer and we continue to innovate on that technology. I would mention that we are the pioneers of RNA editing. So ADAR-mediated RNA editing ...